Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading LSTA daily closes…
Loading price history…
Pipeline assets
Certepetide
Phase 2 · ActiveModality: peptide
Target CendR (C-end rule) pathway
Partnerships SBP: worldwide royalty-bearing license to patent rights and know-how for certepetide. Qilu Pharmaceutical (Greater China exclusive license, up to $200M milestones + 10-15% royalties): agreement terminated effective January 23, 2026; Qilu completed enrollment in the Phase 2 CEND1-202 study in first-line mPDAC. Kuva Labs license/collaboration (Nov 2024): terminated; related merger agreement (March 2026) also terminated
Status note Investigational iRGD peptide from the CendR Platform leveraging the C-end rule active transport mechanism to address tumor stroma. Subject of multiple Phase 1/2 trials including the Phase 2 ASCEND trial (with SoC gemcitabine/nab-paclitaxel) and the completed Phase 2a BOLSTER trial; Phase 3 readiness activities in mPDAC (CMC) delayed per the filing.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.